Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Purple Biotech Says Determined 100Mg/Kg Is The Recommended Phase 2 Dose For NT219 In Combination With Cetuximab In The Treatment Of Head And Neck Cancer Based On Its Phase 1/2 Dose Escalation Study

Author: Benzinga Newsdesk | February 01, 2024 08:38am

NT219 is a first-in-class small molecule dual inhibitor of IRS1/2 and STAT3. The Phase 1 dose escalation study is being concluded and the remaining patients' data are expected to be reported during the first half of 2024.

Posted In: PPBT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist